Trevi Therapeuitcs Names William J. O'Shea to Board and Establishes a Clinical Advisory Board  
3/26/2013 8:09:57 AM

Trevi Therapeutics, Inc., (“Trevi”) a drug development company focused on developing Nalbuphine ER for pruritus, announced today that it has named William J. O'Shea to its Board of Directors and established a Clinical Advisory Board to provide clinical and scientific input into the development strategy for Nalbuphine ER.